What is DA Davidson’s Forecast for USNA Q1 Earnings?

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at DA Davidson issued their Q1 2025 earnings per share estimates for USANA Health Sciences in a report released on Tuesday, February 25th. DA Davidson analyst C. Xue anticipates that the company will post earnings per share of $0.83 for the quarter. DA Davidson currently has a “Neutral” rating and a $38.00 target price on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.15. The firm had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Other equities analysts have also recently issued reports about the stock. Sidoti cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.

USANA Health Sciences Stock Down 2.4 %

USNA stock opened at $31.90 on Wednesday. USANA Health Sciences has a 52 week low of $30.13 and a 52 week high of $50.32. The business has a 50-day simple moving average of $33.65 and a 200 day simple moving average of $36.64. The company has a market cap of $607.96 million, a PE ratio of 11.27, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC boosted its stake in shares of USANA Health Sciences by 111.9% in the 3rd quarter. Barclays PLC now owns 27,737 shares of the company’s stock valued at $1,052,000 after purchasing an additional 14,647 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in USANA Health Sciences by 14,068.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock valued at $1,472,000 after buying an additional 38,547 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of USANA Health Sciences by 13.5% during the third quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company’s stock worth $4,702,000 after buying an additional 14,756 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of USANA Health Sciences by 4.5% during the third quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock worth $11,269,000 after buying an additional 12,898 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of USANA Health Sciences by 0.6% during the third quarter. State Street Corp now owns 435,164 shares of the company’s stock worth $16,501,000 after buying an additional 2,782 shares in the last quarter. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.